Zymo Application Yanked in EU
Luke Timmerman12/14/09
ZymoGenetics (NASDAQ: ZGEN), the Seattle-based developer of a treatment to stop excess surgical bleeding, said today that its partner has voluntarily withdrawn an application to market the product in Europe. Germany-based Bayer, who formed a collaboration with ZymoGenetics to market recombinant thrombin (Recothrom) in 2007, withdrew the European application after regulators there said another clinical trial would be necessary to win approval, according to a regulatory filing. The drug won FDA clearance in January 2008. The product has gotten off to a slow start in the U.S., where it is estimated to generate $28 million to $30 million in sales this year.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
